Matches in Wikidata for { <http://www.wikidata.org/entity/Q66066334> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q66066334 description "assaig clínic" @default.
- Q66066334 description "clinical trial" @default.
- Q66066334 description "clinical trial" @default.
- Q66066334 description "clinical trial" @default.
- Q66066334 description "clinical trial" @default.
- Q66066334 description "ensaio clínico" @default.
- Q66066334 description "ensayo clínico" @default.
- Q66066334 description "ensayu clínicu" @default.
- Q66066334 description "essai clinique" @default.
- Q66066334 description "klinisch onderzoek" @default.
- Q66066334 description "клінічне випробування" @default.
- Q66066334 description "կլինիկական փորձարկում" @default.
- Q66066334 name "Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (M" @default.
- Q66066334 name "Efficacy and Safety of Pembrolizumab" @default.
- Q66066334 type Item @default.
- Q66066334 label "Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (M" @default.
- Q66066334 label "Efficacy and Safety of Pembrolizumab" @default.
- Q66066334 prefLabel "Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (M" @default.
- Q66066334 prefLabel "Efficacy and Safety of Pembrolizumab" @default.
- Q66066334 P1132 Q66066334-8D781B5E-EC40-45AF-81D7-2EBC3119F02A @default.
- Q66066334 P1476 Q66066334-0DFCEA52-B2CE-4A60-AE51-ACCC19E6F2E0 @default.
- Q66066334 P17 Q66066334-17F25708-00D4-4AB0-9FFE-B91461FEE5EE @default.
- Q66066334 P17 Q66066334-19634EAF-E6A1-4850-A8A8-833FE49F0D1F @default.
- Q66066334 P17 Q66066334-78F60338-1FE4-4129-A66D-1591F8CC9DE2 @default.
- Q66066334 P17 Q66066334-9BF25EC1-C657-4379-A38F-CD7D630945A1 @default.
- Q66066334 P17 Q66066334-FDC2672A-A6C4-487E-A3B2-2C18CB7409DE @default.
- Q66066334 P2899 Q66066334-80F76AA5-7EA7-4177-9E8A-513B3F1DC0B7 @default.
- Q66066334 P3098 Q66066334-9EC993FA-7C3F-463D-A7DE-4842B08FB422 @default.
- Q66066334 P31 Q66066334-75707249-4C01-415D-B407-84A163BB4D42 @default.
- Q66066334 P4844 Q66066334-C9080525-2244-440A-9031-B5C85C2E2005 @default.
- Q66066334 P580 Q66066334-464C2E22-77C6-40A1-9125-0708E68B8F37 @default.
- Q66066334 P582 Q66066334-53EA2696-039C-48D2-8681-6A500B1299BE @default.
- Q66066334 P6099 Q66066334-5585524B-D15A-4CE5-A18A-6D14B72D295C @default.
- Q66066334 P8363 Q66066334-233C119E-70A0-4815-9103-FFC67BE180A5 @default.
- Q66066334 P1132 "+405" @default.
- Q66066334 P1476 "A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (Anti-PD-1/PD-L1 Inhibitor) (LEAP-008)" @default.
- Q66066334 P17 Q145 @default.
- Q66066334 P17 Q29 @default.
- Q66066334 P17 Q30 @default.
- Q66066334 P17 Q408 @default.
- Q66066334 P17 Q801 @default.
- Q66066334 P2899 "+18" @default.
- Q66066334 P3098 "NCT03976375" @default.
- Q66066334 P31 Q30612 @default.
- Q66066334 P4844 Q13896859 @default.
- Q66066334 P580 "2019-06-26T00:00:00Z" @default.
- Q66066334 P582 "2023-08-21T00:00:00Z" @default.
- Q66066334 P6099 Q42824827 @default.
- Q66066334 P8363 Q78089383 @default.